Literature DB >> 2376256

Pulmonary hypertension and fenfluramine.

H M Pouwels1, J L Smeets, E C Cheriex, E F Wouters.   

Abstract

Fenfluramine is a widely prescribed anorectic drug as adjuvant therapy for obesity. Pulmonary vascular hypertension after use of fenfluramine is rarely reported. We present a patient with pulmonary hypertension and right heart failure after treatment with fenfluramine. Pulmonary hypertension resolved after withdrawal of the drug.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2376256

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


  7 in total

Review 1.  Respiratory toxicities from stimulant use.

Authors:  T E Albertson; W F Walby
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 2.  Dietary pulmonary hypertension.

Authors:  J M Kay
Journal:  Thorax       Date:  1994       Impact factor: 9.139

3.  Exploration of the pulmonary circulation. Festschrift to Professor Donald Heath.

Authors: 
Journal:  Thorax       Date:  1994       Impact factor: 9.139

Review 4.  Dexfenfluramine. An updated review of its therapeutic use in the management of obesity.

Authors:  R Davis; D Faulds
Journal:  Drugs       Date:  1996-11       Impact factor: 9.546

5.  Effect of (-)-trans-PAT, a novel 5-HT2C receptor agonist, on intake of palatable food in mice.

Authors:  Neil E Rowland; Erica M Crump; Nancy Nguyen; Kimberly Robertson; Zhuming Sun; Raymond G Booth
Journal:  Pharmacol Biochem Behav       Date:  2008-07-19       Impact factor: 3.533

6.  Appetite suppressants and primary pulmonary hypertension in the United Kingdom.

Authors:  S H Thomas; A Y Butt; P A Corris; J J Egan; T W Higenbottam; B P Madden; P C Waller
Journal:  Br Heart J       Date:  1995-12

7.  Primary pulmonary hypertension and fenfluramine use.

Authors:  F Brenot; P Herve; P Petitpretz; F Parent; P Duroux; G Simonneau
Journal:  Br Heart J       Date:  1993-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.